ELTP News 0.3795 04/28/2014 05:20:13 Elite Pharma Inc (ELTP)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Elite Pharma Inc (ELTP) 0.3795 $ELTP

Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
GlobeNewswire - Tue Apr 22, 6:41AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has three US patents and one Canadian patent issued in this area with additional patents pending in the U.S., Canada and Europe.

Limitless Venture Group Settles $163,391 Note with Beaufort Capital Partners
ACCESSWIRE - Wed Apr 16, 9:07AM CDT
Limitless Venture Group Inc.'s (OTCPINK: LVGI) announced that the company and a third- party debt holder Beaufort Capital Partners reached an amicable settlement regarding an outstanding note which had essentially floorless convertible terms attached.

Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC" , a Chicago-based institutional investor for up to $40 million.

Elite Pharmaceuticals, Inc. Secures Funding Commitment of Up to $40 Million From Lincoln Park Capital Fund, LLC
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC" , a Chicago-based institutional investor for up to $40 Million. Proceeds from the transaction will be used to develop the Company's pipeline of products, including the abuse resistant opioids, and for general corporate purposes.

Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
GlobeNewswire - Thu Mar 27, 11:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced that it has created the position of Vice President, Quality Operations & Regulatory Affairs and has hired industry veteran, Barbara Ellison, to fill that role. Ms. Ellison has extensive experience in quality assurance, regulatory compliance, validation, performance optimization and quality control. Ms. Ellison will have overall responsibility for Elite's quality and regulatory functions including the Company's Quality Assurance and Compliance group and the Analytics and Quality Control group. Ms. Ellison will serve as a member of Elite's senior leadership team, reporting directly to Nasrat Hakim, Elite's President and Chief Executive Officer.

OTC Daily Alert Stock Watch - Elite Pharmaceuticals, Inc. (OTCQB: ELTP)
WorldStockWire - Tue Mar 25, 7:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Elite Pharmaceuticals submits site transfer application of Isradipine under FDA's CBE-30
M2 - Tue Mar 25, 5:55AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the submission of a supplemental application with the US Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to its Northvale facility.

Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being Effected in 30 Days (CBE-30) supplemental application with the U.S. Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to Elite's Northvale facility.

Applied Materials Named a 2014 World's Most Ethical Company; KeyCorp Reported 2014 Company Run Stress Test Results and Process
ACCESSWIRE - Thu Mar 20, 11:29PM CDT
KeyCorp. (NYSE: KEY) - For an in-depth report on KeyCorp. follow: www.BullTrends.com/stockquote/KEY

Elite Pharmaceuticals awarded abuse deterrent technology patent in Canada, reflecting a rise in its intellectual property protection
M2 - Tue Mar 11, 6:09AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the receipt of the Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" in Canada.

Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
GlobeNewswire - Mon Mar 10, 6:47AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding the Company's abuse deterrent technology with the issuance of Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance expands the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
GlobeNewswire - Wed Mar 05, 6:30AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated in January 2014 for Elite's undisclosed abuse deterrent opioid product, ELI-200. The study results demonstrated Elite's product is bioequivalent to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) for opioid blood plasma levels. The study was a single dose, open label, partially randomized, three-way cross over study in healthy volunteers with 42 subjects under fasted conditions and 38 subjects under fed conditions.

Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
GlobeNewswire - Tue Feb 18, 6:00AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" ("Elite" (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study initiated in December 2013 for ELI-201, a twice-daily opioid abuse deterrent oxycodone product with abuse deterrent technology. Three different twice daily formulations developed by Elite were tested in the study. The study results demonstrate that all formulations in the study were bioequivalent to the reference drug based on pharmacokinetic measures including peak plasma concentration (Cmax) and area under the curve (AUC) for oxycodone blood plasma levels. The study was a single dose, open label, randomized, four period, four treatment, cross over study in 16 healthy volunteers under fasted conditions.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014
GlobeNewswire - Fri Feb 14, 8:49AM CST
Revenues Increase by 154%, Product Development Accelerating

Prolexic Publishes Infographic on Largest Attacks Mitigated in 2013
M2 - Fri Feb 14, 8:07AM CST
Prolexic Technologies, the global leader in Distributed Denial of Service (DDoS) protection services, today published a new infographic summarizing the statistics about the largest DDoS attacks it mitigated in each quarter of 2013.

Elite Pharmaceuticals, Inc. to Host Third Quarter Business Update Call on February 18, 2014
GlobeNewswire - Mon Feb 10, 2:27PM CST
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations and generics with high barriers to entry, announced today that management will host a conference call to provide a quarterly business update at 3:00 PM ET on Tuesday, February 18, 2014. Company executives will also conduct a question and answer session following their remarks.

Elite Pharmaceuticals Analyst Report offers Insight and Market Data by BrokerBank Securities, Inc.
PR Newswire - Mon Feb 10, 6:00AM CST
Elite Pharmaceuticals Inc. (OTCQB: ELTP) is a specialty pharmaceutical company that is principally engaged in the research, development, and the licensing of proprietary controlled-release drug delivery systems and products. Elite Pharmaceuticals was founded in 1984 and is headquartered in Northvale, New Jersey.

Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product
GlobeNewswire - Tue Jan 14, 12:21PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" ("Elite" (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for an undisclosed opioid abuse deterrent product utilizing Elite's proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals Inc reports launch of pilot bioequivalence study of ELI-201 in alcohol & opioid dependence
M2 - Fri Dec 06, 10:00AM CST
Controlled release products company Elite Pharmaceuticals Inc (OTC BB:ELTP) reported on Thursday the start of dosing of a first pilot bioequivalence study in healthy volunteers for its twice daily abuse deterrent oxycodone/naltrexone product, ELI-201.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

191 Schools Honored for Academic Growth Success

Updated Category News Views 44

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 34

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 176

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 59

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 12

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 259

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 120

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Boot Barn Holdings Inc's Updated Short Interest Trends

Updated Category News Views 216

Boot Barn Holdings Inc Short Interest Overview Boot Barn Holdings Inc (NYSE: BOOT) recently reported a decrease in its short interest as a percentage of the float, showing a 3.28% drop since the last report. Currently, there are approximately 3.45 million shares sold short, representing 15.33% of all the regular shares available for trading. Based on recent trading...

Continue Reading
Kura Oncology's Inducement Grants: Enhancing Employment Opportunities

Updated Category News Views 138

Kura Oncology's New Inducement Grants for Employees Kura Oncology, Inc., a prominent clinical-stage biopharmaceutical company, has recently made headlines with its innovative approach to employee engagements. This dynamic company is dedicated to the advancement of precision medicines that promise better treatments for cancer patients. To strengthen its workforce, Kura...

Continue Reading
Star Power and Dark History Fuel 'Hell's Half-Acre'

Updated Category News Views 70

A Gripping True Crime Tale Hits the Screen Does the open prairie of the 1870s Kansas and a family of killers strike a chill down your spine? If not, just wait until you get an eyeful of 'Hell's Half-Acre,' a film delving into America's first serial killing 'family.' Nicholas Nicastro, not one to shun bold storytelling, is the power wheel behind this upcoming...

Continue Reading
The Block Unveils Campus: A New Era in Crypto Education

Updated Category News Views 371

The Block Unveils Campus: A Revolutionary Education Platform The Block has unveiled its latest initiative, Campus by The Block, a comprehensive education and certification platform tailored specifically for the crypto industry. This innovative platform was introduced during The Block's inaugural global conference, highlighting its commitment to overcoming the challenges...

Continue Reading
Makino Milling Seeks Modifications to Nidec's Takeover Proposal

Updated Category News Views 825

Makino Milling Requests Changes to Nidec's Bid In a recent statement, Japanese machine tool manufacturer Makino Milling Machine has actively engaged with Nidec regarding an unsolicited takeover bid. This interaction highlights the ongoing dynamics within the industrial machinery sector and reflects the strategic decisions being made by companies in Japan. Details of the...

Continue Reading